Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

MedicineMan777 Jun. 14 at 5:37 PM

$TCRX This from TCRX annual report for principal stock holders. Capital Management LP beneficially owned 8,019,148 shares, representing 14.36% of TScan Therapeutics’ outstanding common stock. Entities affiliated with Biotechnology Value Fund, L.P. beneficially owned 8,165,331 shares, representing 14.63% of the company’s common stock. Entities affiliated with K2 HealthVentures Equity Trust LLC beneficially owned 3,602,700 shares, representing 6.45% of the outstanding shares. Entities affiliated with Baker Bros. Advisors LP beneficially owned 2,785,698 shares, representing 4.99% of the company’s common stock. All insiders own 6.25% of the company’s outstanding common stock.

0 · Reply

MedicineMan777 Jun. 14 at 4:29 PM

$TCRX Institutional investors Lynx1 Capital Management LP:8.0 million~12–13% BVF Partners L.P. 5.2–5.6 million~8.5–8.7% Baker Bros. Advisors LP:2.8 million~4.3–4.6% The Vanguard Group: 2.5 million ~4.1% BlackRock:1.8 million~2.8–3.1% Renaissance Technologies:1.36 million~2.1–2.3% Deer Management Co.:1.25 million~1.9–2.1% Two Sigma Investments:1.21 million~1.8–1.9%

0 · Reply

JSP_Dilution_Player Jun. 12 at 6:41 PM

Holding below into next week unless something changes by EOD. $TCRX - data news ahead and trading way below cash. $99 million owner's equity vs $59 million market cap as of 3/31. $MREO FDA meeting news ahead. Funds into Mid 2027. $GOSS FDA news ahead. Some more tutes filing out and more likely ahead based on last 2 days of volume.

0 · Reply

FrankCiro Jun. 12 at 6:22 PM

$TCRX volumes still low, we are now buying on the downside to try to make a good profit in the short but above all in the long term. Great pipeline

0 · Reply

JSP_Dilution_Player Jun. 12 at 1:50 PM

$TCRX send it over $1. they got ton of cash. better hold .90.

0 · Reply

JSP_Dilution_Player Jun. 11 at 4:30 PM

$TCRX this management needs to put out good PRs. Trading below cash.

0 · Reply

suredubb Jun. 9 at 8:16 PM

$TCRX tutes are loading up.. bottom of 6 month base.. great time to scale in

1 · Reply

FrankCiro Jun. 7 at 1:58 PM

$TCRX long this is a beautiful experience, great pipeline

0 · Reply

Mmmm1319 Jun. 6 at 2:20 AM

$TCRX

0 · Reply

ducruacuteo11 Jun. 5 at 5:40 PM

$TCRX Is this alive or dead? LOL. C'mon, TCRX, give me that great Cohort C and Phase 3 announcements. $6 by yearend?

1 · Reply

TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing

Jun 3, 2026, 9:19 AM EDT - 11 days ago

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

May 20, 2026, 8:30 AM EDT - 25 days ago

TScan Therapeutics Transcript: AGM 2026

2026-05-07T07:41:39.000Z - 5 weeks ago

TScan Therapeutics reports Q1 EPS (22c), consensus (17c)

May 6, 2026, 7:00 AM EDT - 5 weeks ago

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026, 7:00 AM EDT - 5 weeks ago

TScan Therapeutics Earnings release: Q1 2026

May 6, 2026, 7:00 AM EDT - 5 weeks ago

TScan Therapeutics Quarterly report: Q1 2026

Apr 27, 2026, 4:30 PM EDT - 6 weeks ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

Apr 17, 2026, 8:00 AM EDT - 2 months ago

TScan Therapeutics Proxy statement: Proxy filing

Apr 15, 2026, 3:00 PM EDT - 2 months ago

TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 7:00 AM EDT - 2 months ago

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 2 months ago

TScan Therapeutics Proxy statement: Proxy filing

2026-03-05T14:05:02.000Z - 3 months ago

TScan Therapeutics price target raised to $5 from $4 at Wedbush

Mar 4, 2026, 11:50 AM EST - 3 months ago

TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-03-04T12:11:24.000Z - 3 months ago

TScan Therapeutics reports Q4 EPS (18c), consensus (28c)

2026-03-04T12:10:31.000Z - 3 months ago

TScan Therapeutics sees cash runway into 2H27

Mar 4, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 4, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics Annual report: Q4 2025

Mar 4, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics Earnings release: Q4 2025

Mar 4, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics Slides: Corporate presentation

2026-02-26T12:36:57.000Z - 3 months ago

TScan Therapeutics completes enrollment into Cohort C of ALLOHA study

Feb 26, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

Feb 25, 2026, 7:00 AM EST - 3 months ago

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Dec 8, 2025, 8:00 AM EST - 6 months ago

TScan Therapeutics Transcript: KOL Event

Dec 8, 2025, 8:00 AM EST - 6 months ago

TScan Therapeutics Press release: KOL Event

Dec 8, 2025, 8:00 AM EST - 6 months ago

TScan Therapeutics Slides: KOL Event

2025-12-07T18:30:11.000Z - 6 months ago

TScan Therapeutics announces updated data from ALLOHA Phase 1 trial

Dec 3, 2025, 4:05 PM EST - 6 months ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

Nov 26, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics Slides: Corporate Presentation

2025-11-14T00:55:25.000Z - 7 months ago

TScan Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley

Nov 12, 2025, 10:00 AM EST - 7 months ago

TScan Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

2025-11-12T12:10:19.000Z - 7 months ago

TScan Therapeutics reports Q3 EPS (28c), consensus (33c)

Nov 12, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics Quarterly report: Q3 2025

Nov 9, 2025, 6:00 PM EST - 7 months ago

TScan Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 7:00 AM EST - 7 months ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

2025-11-04T11:16:37.000Z - 7 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-04T11:10:09.000Z - 7 months ago

TScan Therapeutics downgraded to Neutral from Buy at BTIG

2025-11-03T19:05:38.000Z - 7 months ago

TScan Therapeutics price target lowered to $6 from $9 at Needham

Nov 3, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Transcript: FDA Announcement

Nov 3, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Press release: FDA Announcement

Nov 3, 2025, 8:00 AM EST - 7 months ago

TScan Therapeutics Slides: FDA Announcement

2025-11-03T11:50:39.000Z - 7 months ago

TScan Therapeutics to reduce workforce by 30%

Nov 3, 2025, 6:30 AM EST - 8 months ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 9 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 10, 2025, 9:00 AM EDT - 9 months ago

TScan Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 5:35 PM EDT - 9 months ago

TScan Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

2025-08-12T11:05:34.000Z - 10 months ago

TScan Therapeutics reports Q2 EPS (28c), consensus (32c)

2025-08-12T11:05:19.000Z - 10 months ago

TScan Therapeutics expects cash to fund operations into Q1 of 2027

Aug 12, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 7:00 AM EDT - 10 months ago

TScan Therapeutics Earnings release: Q2 2025

Jun 4, 2025, 4:55 PM EDT - 1 year ago

TScan Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

TScan Therapeutics Proxy statement: Proxy Filing

May 14, 2025, 8:00 AM EDT - 1 year ago

TScan Therapeutics Proxy statement: Proxy Filing

May 13, 2025, 6:40 PM EDT - 1 year ago

TScan Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

2025-05-12T19:00:24.000Z - 1 year ago

TScan Therapeutics management to meet virtually with BTIG

2025-05-07T10:16:13.000Z - 1 year ago

TScan Therapeutics price target lowered to $10 from $15 at H.C. Wainwright

2025-05-06T11:06:17.000Z - 1 year ago

TScan Therapeutics reports Q1 EPS (26c), consensus (28c)

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Quarterly report: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Earnings release: Q1 2025

May 6, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Slides: Q1 2025

Apr 28, 2025, 4:53 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Apr 7, 2025, 9:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 31, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

2025-03-27T11:25:33.000Z - 1 year ago

TScan Therapeutics appoints Camiolo as SVP, Market Access

Mar 27, 2025, 7:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 5, 2025, 1:10 PM EST - 1 year ago

TScan Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Annual report: Q4 2024

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Earnings release: Q4 2024

Mar 5, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Registration statement: Registration Filing

Feb 27, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 10:00 AM EST - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 18, 2025, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Dec 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Transcript: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Press release: Status Update

Dec 10, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Slides: Status Update

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 12, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Sep 10, 2024, 9:00 AM EDT - 1 year ago

TScan Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 5, 2024, 8:30 AM EDT - 1 year ago

TScan Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Quarterly report: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Earnings release: Q2 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Slides: Company Presentation

Jun 14, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 30, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Proxy statement: Proxy Filing

Apr 30, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Proxy statement: Proxy Filing

Apr 24, 2024, 4:05 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 2 years ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 2 years ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 2 years ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 2 years ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 2 years ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 2 years ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 2 years ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Earnings release: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Annual report: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Registration statement: Registration Filing

Feb 28, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

MedicineMan777 Jun. 14 at 5:37 PM

0 · Reply

MedicineMan777 Jun. 14 at 4:29 PM

0 · Reply

JSP_Dilution_Player Jun. 12 at 6:41 PM

0 · Reply

FrankCiro Jun. 12 at 6:22 PM

$TCRX volumes still low, we are now buying on the downside to try to make a good profit in the short but above all in the long term. Great pipeline

0 · Reply

JSP_Dilution_Player Jun. 12 at 1:50 PM

$TCRX send it over $1. they got ton of cash. better hold .90.

0 · Reply

JSP_Dilution_Player Jun. 11 at 4:30 PM

$TCRX this management needs to put out good PRs. Trading below cash.

0 · Reply

suredubb Jun. 9 at 8:16 PM

$TCRX tutes are loading up.. bottom of 6 month base.. great time to scale in

1 · Reply

FrankCiro Jun. 7 at 1:58 PM

$TCRX long this is a beautiful experience, great pipeline

0 · Reply

Mmmm1319 Jun. 6 at 2:20 AM

$TCRX

0 · Reply

ducruacuteo11 Jun. 5 at 5:40 PM

$TCRX Is this alive or dead? LOL. C'mon, TCRX, give me that great Cohort C and Phase 3 announcements. $6 by yearend?

1 · Reply

BigD_Love Jun. 4 at 8:42 PM

$TCRX Hopefully we will get some data at EHA being held June 11-14th in Sweden… Also, below is more news released yesterday GLTA! 👊🏻 https://ir.tscan.com/news-releases/news-release-details/cellares-and-tscan-therapeutics-announce-agreement-evaluate

0 · Reply

JSP_Dilution_Player Jun. 4 at 7:50 PM

$TCRX look at the recent block buys on this undervalued stock. Catalyst ahead

0 · Reply

Tootimus Jun. 3 at 2:44 PM

$TCRX picked up a few here. This will be a good long term investment.

0 · Reply

DARKP00L Jun. 3 at 1:22 PM

$TCRX 09:22 on Jun. 03 2026 TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes #tradeideas

0 · Reply

BigD_Love Jun. 2 at 10:19 PM

$TCRX We’rent they supposed to drop data from ASCO? I wonder why we are still waiting…

0 · Reply

xpro123 Jun. 2 at 3:04 PM

$TCRX ok ok fine I’ll add

0 · Reply

signaljumper Jun. 1 at 2:27 PM

$TCRX 👀👀

0 · Reply

Rjinvestments88 May. 29 at 7:35 PM

$TCRX 👀 this may start to accumulate $BYND still holding from .58 just to see if we squeeze up like $STRIVE as i held and paid off 🚀

0 · Reply

Rjinvestments88 May. 29 at 7:30 PM

$TCRX TScan Therapeutics Inc has a consensus price target of $8 based on the ratings of 8 analysts. The high is $15 issued by HC Wainwright & Co. on March 6, 2025. The low is $3 issued by Barclays on March 7, 2025. The 3 most-recent analyst ratings were released by Wedbush, HC Wainwright & Co., and Needham on March 5, 2026, November 13, 2025, and November 4, 2025, respectively. With an average price target of $6 between Wedbush, HC Wainwright & Co., and Needham, there's an implied 455.56% upside for TScan Therapeutics Inc from these most-recent analyst ratings.

0 · Reply

GangsterX May. 28 at 3:15 PM

$TCRX $GERN hold it.. cant lose

0 · Reply

JSP_Dilution_Player May. 27 at 2:04 PM

$TCRX back to 1.20 soon

0 · Reply

suredubb May. 26 at 6:54 PM

$TCRX tons of little volume spikes…. accumulation

0 · Reply

Market Cap	59.61M
Revenue (ttm)	10.33M
Net Income (ttm)	-129.77M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,256.24%
Debt to Equity Ratio	0.34

Volume	380,200
Avg Vol	891,116
Day's Range	N/A - N/A
Shares Out	65.35M
Stochastic %K	6%
Beta	1.03
Analysts	Strong Sell
Price Target	$6.80